1135 Absence of difference between bone marrow or peripheral stem cells as source of hemopoietic support for high dose therapy in breast cancer

From March 1992 to August 1994 62 patients received high dose therapy either as intensification fur high risk breast cancer (31) or metastatic disease (31). Combination chemotherapy employed was: Cyclophosphamide (1.5 g/m 2  × 4 days), carboplatin (200 mg/m 2  × 4 days continuous infusion) and thiotepa (125 mg/m 2 /4 days, continuous infusion). Conventional bone marrow harvested was used as a source of hemopoietic support in 37 patients. In all cases subcutaneous G-CSF was administered from day + 1 until neutrophil engraftment at a dose of 5 microg/k/day. In the rest 25 patients G-CSF mobilized peripheral blood stem cells were infused after high-dose therapy. Eleven out of 25 received G-CSF after the transplant in the same schedule than bone marrow transplant patients. The aim of this study was to analyze if there were difference in terms of engraftment, days of hospitalization, and requirements of transfusion between this groups.